Endostatin is a naturally occurring protein fragment derived from collagen XVIII, known for its potent anti-angiogenic properties. It functions by inhibiting the proliferation and migration of endothelial cells, which are essential for new blood vessel formation. As such, endostatin plays a key role in regulating angiogenesis — the process by which new blood vessels grow — and is typically expressed in the extracellular matrix. Its presence is particularly important in the context of tumor growth and metastasis, where angiogenesis is crucial for providing nutrients to expanding tumor tissue.
In clinical and research settings, endostatin is widely studied as both a biomarker and a therapeutic agent. As a biomarker, elevated or reduced levels of endostatin in serum or tissue samples can indicate alterations in angiogenic balance, which is relevant in cancer, cardiovascular diseases, and certain inflammatory conditions. Clinically, recombinant forms of endostatin have been investigated in oncology for their potential to suppress tumor vascularization and growth. In research, endostatin is used in angiogenesis assays, tumor models, and drug development to explore mechanisms of vascular inhibition and to assess anti-cancer therapies targeting the tumor microenvironment. Its anti-angiogenic properties make it a valuable tool in both basic and translational studies.
This product is manufactured in Austria by Biomedica.